Nocion Therapeutics

A 2 a.m. cough that no medicine can fix - and the lab that took it personally.

Somewhere right now, someone is awake at 2 a.m. coughing for the eleven-hundredth time today. They have seen the specialists. They have tried the syrups, the inhalers, the off-label antidepressants. Nothing worked, because in the United States there is no drug approved to treat what they have. Refractory chronic cough is a condition that medicine has, until recently, mostly shrugged at.

Nocion Therapeutics is an 18-person company in Watertown, Massachusetts that decided the shrug was unacceptable. It is clinical-stage, venture-backed, and stubbornly focused on a single, unfashionable idea: that you can quiet an overactive nerve without numbing everything around it. Its lead candidate, an inhaled powder called taplucainium, is now in a fully enrolled Phase 2b trial. The company has raised roughly $122 million to find out if the idea holds.

It is, on paper, a respiratory company. In practice it is something stranger and more ambitious: a bet that a single clever piece of chemistry can reach far past cough - into itch, into chronic pain, into a long list of conditions where nerves fire when they shouldn't.

Pain relief has always been a blunt instrument.

Here is the inconvenient truth about numbing things. Lidocaine, the workhorse local anesthetic, doesn't discriminate. Inject it and it shuts down every nerve it can reach - the ones causing trouble and the ones quietly doing their jobs. That is why your whole jaw goes dead at the dentist when the problem is one tooth. Effective, yes. Elegant, no.

The body's alarm system runs on nociceptors: sensory neurons whose entire purpose is to detect damage and report it as pain, itch, or the urge to cough. Useful, mostly. But when they get inflamed and stuck in the "on" position, they keep screaming long after the threat is gone. That is chronic cough. That is chronic itch. That is a large share of chronic pain.

The fashionable answer in cough has been P2X3 receptor antagonists - drugs that block one specific channel. Merck spent years on gefapixant; the FDA rejected it twice. GSK paid roughly $2 billion for Bellus Health to get one of its own. The category is crowded, and it leans on blocking a single door. Nocion looked at the crowd and decided to walk through a different door entirely.

Two Harvard neuroscientists gave a molecule a charge - and a conscience.

The science came out of two labs at Harvard Medical School and Boston Children's Hospital. Bruce Bean, a professor of neurobiology, and Clifford Woolf, one of the field's most cited pain researchers, asked a deceptively simple question: what if a drug could only get inside the neurons that were already firing?

Their insight was chemical. Give a sodium-channel blocker a permanent positive charge and it can no longer slip through cell membranes on its own - the usual way these drugs get everywhere. But an inflamed, actively firing nociceptor temporarily opens large-pore channels (P2X, TRPV, TRPA). Those open pores become a private entrance. The charged molecule rides in only where the trouble is, blocks the sodium channels that keep the neuron firing, and leaves every calm neuron untouched.

They called the resulting molecules nocions, after the nociceptors they target. The company - Nocion Therapeutics - was founded in 2017 and licensed the technology from Harvard and Boston Children's Hospital. Co-founder Bruce Levy and CEO Richard Batycky rounded out the launch. Batycky had done this before: he co-founded Civitas Therapeutics, an inhaled-drug company acquired by Acorda in 2014. Betting the lead program on an inhaled powder was, you might say, on brand.

From a Harvard whiteboard to a Phase 2b readout.

Taplucainium: an inhaled powder with a velvet rope.

Taplucainium (formerly NTX-1175, dosed as NOC-110) is a dry powder you breathe in. Once it reaches the lungs, it cannot force its way into healthy nerve cells - the charge sees to that. It waits at the door. The only neurons that let it in are the inflamed, hyperactive ones whose large-pore channels are already open. It is a velvet rope policy: members only, and the membership requirement is "currently malfunctioning."

That selectivity is the entire pitch. Block the sodium channels inside those firing neurons and you interrupt the runaway signal driving the cough - locally, durably, and without the systemic exposure or off-target numbing that comes with conventional anesthetics. Compared with P2X3 antagonists, which jam one specific receptor, taplucainium slips in through whichever large-pore channel happens to be open and works downstream at the sodium channel itself.

And the platform doesn't stop at lungs. The same trick - charge plus open pore - applies anywhere nociceptors fire when they shouldn't. The company's keyword cloud reads like a tour of conditions people rarely talk about: chronic itch, post-herpetic neuralgia, vulvodynia, interstitial cystitis, ocular pain, burning mouth syndrome. Cough is the proving ground. The map is much larger.

Money, mechanism, and a pedigree that funds itself.

Skeptics are right to ask what backs the story. Three things, so far. First, the money: roughly $122 million across a Series A and a Series B, with the latter co-led by Arkin Bio Capital and Monograph Capital and topped up by existing investors in early 2026. Investors who have seen many cough pitches chose to write this one a large check.

Second, the mechanism has been presented at venues that don't suffer hand-waving gladly - including the London International Cough Symposium, where the company laid out preclinical and clinical data on taplucainium as a charged sodium channel blocker. Third, the pedigree: the science traces directly to Bean and Woolf, two names that carry weight in neurobiology, and the IP came out of Harvard's technology development office.

The honest caveat: this is still a clinical-stage company. Revenue is essentially pre-commercial, the headcount is small, and the verdict that matters - whether taplucainium actually quiets cough in a controlled trial - is the 2026 ASPIRE readout. The proof is not yet a product. It is a well-funded, well-credentialed, fully enrolled question.

Silence the alarm without cutting the wires.

The company states its mission plainly: bring long-awaited relief to people with chronic cough and other diseases of sensory neuron hypersensitivity, using a new class of charged sodium channel blockers. Strip away the jargon and it is a promise about restraint - relief that is selective, local, and durable, instead of relief that comes with a side order of numbing everything else.

That restraint is the philosophy. For a century, turning off pain meant turning off function. Nocion's wager is that the next century doesn't have to work that way - that you can quiet the one nerve that won't stop without dimming the whole nervous system. It is a small idea with a very large surface area.

Back to 2 a.m.

Return to the person awake at 2 a.m., coughing for the eleven-hundredth time. For them, the abstractions - charged molecules, large-pore channels, Phase 2b enrollment - collapse into a single question: will it ever stop? Nocion exists to make the answer "yes," and to make it "yes" without trading the cough for a fog.

The data hasn't returned yet. The platform may reach itch and pain, or it may earn its keep on cough alone. But the shape of the idea is clear, and it is the rare biotech story that a non-scientist can hold in one hand: teach the drug to knock only on the doors that are already open. If it works, the 2 a.m. cough doesn't get medicated into submission. It just, finally, stops.